Alternating Doublets: Establishing the Optimal Multifractionated Dosing Schedule to Administer Docetaxel, Cisplatin, Gemcitabine, and Vinorelbine in Combination

References

• Schiller J., Harrington D., Sandler A., et al. A randomized phase III trial of four chemothreapy regimens in advanced non small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Onc. 2000; 19: 1a, Abstract 2. Oral Presentation, Plenary Session
   Google Scholar
• Hainsworth J. D., Burris H. A., Litchy S., Erland J. B., Hon J. K., Brierre J. E., Greco F. A. Gemcitabine and vinorelbine in the second-line treatment of non small cell lung carcinoma patients. A Minnie pearl cancer research network phase II trial. Cancer 2000; 88: 1353–1358
   PubMed Web of Science ®Google Scholar
• Miller V. A., Ng K. K., Krug L. M., Perez W., Pizzo B., Heelan R. T., Kris M. G. Phase I trial of docetaxel and vinorelbine in patients with advanced non small cell lung carcinoma. Cancer 2000; 88: 1045–1050
   PubMed Web of Science ®Google Scholar
• Cappuzzo F., Rocha Lima C. M., Sherman C. A., Green M. R. Advances in treatment of inoperable NSCLC: gemcitabine doublets—a promising alternative. Oncology 2000; 14: 7–14
   PubMedGoogle Scholar
• Comella P. Triple- vs. double-agent chemotherapy for advanced non small cell lung cancer. Oncology 2000; 14: 35–40
   PubMedGoogle Scholar
• Kosmidis P. Oackutaxek/carboplatin vs. paclitaxel/gemcitabine in advanced non small cell lung cancer. Oncology 2000; 14: 41–48
   PubMedGoogle Scholar
• Lilenbaum R., Cano R., Schwartz M., Siegel L., Lutzky J., Lewis M., Krill E., Barreras L., Davila E. Gemcitabine and vinorelbine in advanced non small cell lung carcinoma. Cancer 2000; 88(3)557–562
   PubMed Web of Science ®Google Scholar
• Rizvi N. A., Spiridonidis C. H., David T. H., Bhargava P., Marshall J. L., Dahut W., Figuera M., Hawkins M. J. Docetaxel and gemcitabine combinations in non small cell lung cancer. Semin. Oncol. 1999; 26(Supplement)27–31
   PubMedGoogle Scholar
• Herbst R. S., Lilenbaum R. Gemcitabine and vinorelbine combinations in the treatment of non small cell lung cancer. Semin. Oncol. 1999; 26(Supplement)67–70
   PubMedGoogle Scholar
• Lokich J. Single-dose granulocyte colony-stimulating factor concomitant with multifractionated dose chemotherapy: a strategy for maintaining dose intensity. Cancer Investig. 1999; 17(7)547–550
   PubMed Web of Science ®Google Scholar
• Dragnev K. H., Rigas J. R. The future beyond platinum for the treatment of advanced non small cell lung cancer. Semin. Oncol. 1999; 26(Supplement)73–77
   PubMedGoogle Scholar
• Crino L., Mosconi A. M., Scagliotti F., et al. Salvage therapy with gemcitabine (GEM) in pretreated advanced non small cell lung cancer (NSCLC). Proc. Soc. Clin. Oncol. 1997; 16: 446a, [Abstract]
   Google Scholar
• Rosvold E., Langer C. J., Schilder R., et al. Salvage therapy with gemcitabine in advanced non small cell lung cancer (NSCLC) progressing after carboplatin-paclitaxel (C-P). Proc. Soc. Clin. Oncol. 1998; 17: 467a, [Abstract]
   Google Scholar
• Guerra J. A., Lianes P., Paz-Ares L., et al. Efficiency and toxicity profile of gemcitabine in previously treated patients with non-small cell lung cancer (NSCLC). Lung Cancer 1997; 18(Suppl. 1)28, [Abstract]
   Google Scholar
• Garfield D. H., Dakhil S. R., Whittaker T. L., Keller A. M. Phase II randomized multicenter trial of two dose schedules of gemcitabine as second line therapy in patients with non-small cell lung cancer. Proc. Soc. Clin. Oncol. 1998; 17: 484a, [Abstract]
   Google Scholar
• Fukuoka M., Takada M., Yokoyama A., et al. Phase II studies of gemcitabine for non-small cell lung cancer in Japan. Semin. Oncol. 1997; 24(Suppl. 7)S7–S42
   PubMedGoogle Scholar
• Pronzato P., Landucci M., Vaira F., et al. Failure of vinorelbine to produce responses in pretreated non small cell lung cancer patients. Anticancer Res. 1994; 14: 1413–1415
   PubMed Web of Science ®Google Scholar
• Rinaldi M., Della Giulia M., Venturo I., et al. Vinorelbine as single agent in the treatment of non-small cell lung cancer. Proc. Soc. Clin. Oncol. 1994; 3: 360, [Abstract]
   Google Scholar
• Santoro A., Maiorino L., Santoro M. Second line with vinorelbine in the weekly monochemotherapy for the treatment of advanced non-small cell lung cancer. Proc. Soc. Clin. Oncol. 1994; 11(Suppl. 1)130, [Abstract]
   Google Scholar
• Huisman C., et al. Second line chemotherapy in relapsing or refractory non small cell lung cancer: a review. J. Clin. Oncol. 2000; 18: 3722–3730
   PubMed Web of Science ®Google Scholar
• Lokich J. Multifractionated dosing for cancer chemotherapy: a novel schedule and a work in progress. Cancer Investig. 1999; 17(7)551–554
   PubMed Web of Science ®Google Scholar
• Lokich J. Multifractionated dosing for chemotherapy with flexible cytokine usage: a strategy for optimizing the therapeutic index. Am. J. Clin. Oncol., in press
   Google Scholar
• Gordon G. S., Mauer A. M., Rudin C. M., et al. A phase I/II study of dose-dense “alternating doublets” chemotherapy with filgrastim (RHG-CSF) support in advanced non small cell lung cancer (NSCLC). Proc. ASCO 2000; 19: 526a
   Google Scholar
• Wozniak A. J., Crowley J. J., Balcerzak S. P., et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non small cell lung cancer. A Southwest Oncology group study. J. Clin. Oncol. 1998; 16: 2459–2465
   PubMed Web of Science ®Google Scholar
• Sandler A. B., Nenumaitis J., Denham C., et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non small cell lung cancer. J. Clin. Oncol. 2000; 16: 122–130
   Google Scholar
• Bonomi P., Kim K. M., Fairclough D., et al. Comparison of survival and quality of life in advanced non small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an eastern cooperative group trial. J. Clin. Oncol. 2000; 18: 623–631
   PubMed Web of Science ®Google Scholar
• Langer C. J. Treatment of non-small cell lung cancer in North America: the emerging role of irinotecan. Oncology 2001; 15(Suppl. 1)19–24
   PubMedGoogle Scholar